The ORR for TAS-102 and bevacizumab without leronlimab is 5-10%, low bar there. You have to bear in mind that we're talking 3rd line therapy here; Cytodyn is being allowed this salvage therapy study by the FDA.
As far as approval goes, God knows. Assuming that PD-L1 upregulation occurs and the addition of an ICI blows the doors off the study, and assuming the FDA has really changed its ways, an approval for third line at least as a no-brainer, IMO.